Gilead Sciences (GILD) Tops Q4 EPS by 19c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
February 11, 2025 4:02 PM ESTProduct Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024
Biktarvy Sales Increased 13% Year-Over-Year to $13.4 billion for Full Year 2024
Oncology Sales Increased 12% Year-Over-Year to $3.3 billion for Full Year 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.
Gilead delivered another exceptionally strong full year and fourth quarter, with growth in our base business product sales of 8% for 2024 and 13% year-over-year... More
